In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed last ...

In spring 2021, my family sold a big lump of GSK shares. Four years later, we have no regrets. Indeed, with the GSK share price stumbling, we may buy soon. When investing, your capital is at risk.

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Goldman believes the slides suggest the committee will likely vote to expand its recommended population for GSK‘s (GSK) Arexvy to those aged 50-59. This would represent a “positive surprise ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc. a global biopharma company to unite science technology and talent to get ahead of disease together. The Company is ...